A phase 1 study of first-in-class agent CPI-613 in combination with FOLFIRINOX for metastatic pancreatic cancer

BACKGROUND: Pancreatic cancer statistics are dismal, with a five-year survival of less than 10%, and over 50% of patients presenting with metastatic disease. Metabolic reprogramming is an emerging hallmark of pancreatic adenocarcinoma, including aerobic glycolysis, oxidative phosphorylation, glutami...

Descripción completa

Detalles Bibliográficos
Autores principales: Alistar, Angela, Morris, Bonny B., Desnoyer, Rodwige, Klepin, Heidi D., Hosseinzadeh, Keyanoosh, Clark, Clancy, Cameron, Amy, Leyendecker, John, D’Agostino, Ralph, Topaloglu, Umit, Boteju, Lakmal W., Boteju, Asela R., Shorr, Rob, Zachar, Zuzana, Bingham, Paul M., Ahmed, Tamjeed, Crane, Sandrine, Shah, Riddhishkumar, Migliano, John J., Pardee, Timothy S., Miller, Lance, Hawkins, Gregory, Jin, Guangxu, Zhang, Wei, Pasche, Boris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635818/
https://www.ncbi.nlm.nih.gov/pubmed/28495639
http://dx.doi.org/10.1016/S1470-2045(17)30314-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635818/
https://www.ncbi.nlm.nih.gov/pubmed/28495639
http://dx.doi.org/10.1016/S1470-2045(17)30314-5

Ejemplares similares